For example, an objective response rate (ORR) of 28% was observed with cabozantinib in patients with previously treated RET fusion-positive NSCLC.36 Vandetanib has also demonstrated an ORR of 17% in a similar patient population. Here, RET is linked to non-small cell lung carcinoma.